Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

249.46 -1.36 (-0.54%)
Official Closing Price Updated: 7:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year ↗
AbbVie has another blockbuster business emerging. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗
The drugmaker should significantly mitigate its most important risk as it develops new products. 
Via The Motley Fool
News headline image
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power. 
Via The Motley Fool
Topics Intellectual Property
AbbVie (NYSE:ABBV) Shares Slip on Apogee Acquisition Despite In-Line Q2 Results ↗
Via Chartmill
Cannabis Theme's Hidden Strength: Established Players Outshining Pure Plays ↗
Via Chartmill
Topics Cannabis
News headline image
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
News Provided by USA News Group on behalf of Conexeu Sciences Inc. 
From USA News Group
Via GlobeNewswire
News headline image
2 Reasons to Like ABBV and 1 to Stay Skeptical
AbbVie has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.7% to $249.64 per... 
Via StockStory
Topics Stocks Supply Chain
News headline image
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members. 
Via The Motley Fool
News headline image
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026? ↗
Both of these stocks pay more than double the S&P 500 average of 1.1%. 
Via The Motley Fool
Topics Stocks
News headline image
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry? ↗
The pharmaceutical company hopes that another big-time acquisition will pay off. 
Via The Motley Fool
News headline image
Is AbbVie Stock a Buy After Posting Strong Q2 Earnings? ↗
The stock is up just 8% this year and could prove to be an undervalued buy. 
Via The Motley Fool
News headline image
Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026? ↗
XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns. 
Via The Motley Fool
Topics ETFs Economy
News headline image
MarketBeat Week in Review – 08/03 - 08/07 ↗
A weekly roundup of MarketBeat analysis covering earnings from AbbVie, AMD, Palantir, Meta, Reddit, SpaceX and others, plus upcoming CPI and PPI inflation data. 
Via MarketBeat
Topics Economy Intellectual Property
News headline image
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet. 
Via The Motley Fool
News headline image
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗
This risk is weighing on the stock. 
Via The Motley Fool
News headline image
The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call
AbbVie’s second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales gr... 
Via StockStory
Topics Earnings
News headline image
3 Cash-Producing Stocks for Long-Term Investors
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ... 
Via StockStory
Topics Energy
News headline image
This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now ↗
There is no end in sight for the drugmaker's dividend growth streak. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU) 
From American News Group
Via GlobeNewswire
News headline image
AbbVie (ABBV) Q2 2026 Earnings Call Transcript ↗
Revenue beat guidance as immunology and neuroscience portfolios drive growth. 
Via The Motley Fool
Topics Earnings Economy
News headline image
The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure ↗
As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV). 
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
News headline image
AbbVie Quietly Solved Its Biggest Problem—Now What? ↗
AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300. 
Via MarketBeat
Topics Intellectual Property
News headline image
ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 10.2% year on year to $16.99 ... 
Via StockStory
News headline image
Why AbbVie Stock Slumped Today ↗
The company, one of the rare healthcare sector Dividend Kings, wasn't looking too royal on the last trading day of the week. 
Via The Motley Fool
Topics Earnings
News headline image
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today ↗
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.65% on an annualized basis producing an average annual return of 16.8%. Currently, AbbVie has a market capitalization of... 
Via Benzinga
News headline image
AbbVie Q2 Earnings Call Highlights ↗
AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue... 
Via MarketBeat
Topics ETFs Earnings
News headline image
AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat ↗
AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets. 
Via Benzinga
News headline image
AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue
Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-G... 
Via StockStory
Get insights into the top movers in the S&P500 index of Friday's pre-market session. ↗
Via Chartmill
News headline image
What To Expect From AbbVie’s (ABBV) Q2 Earnings
Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here’s what to look for. AbbVie beat analysts’... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.